Caitlin Costello - Concepedia

Author

Caitlin Costello

University of California San Diego ORCID

Also Known As

C COSTELLO, C Costello, C. Costello, C.L. Costello, Caitlin Costello, Caitlin L Costello, Caitlin L. Costello, Jakubowiak, Andrzej, Nathwani, Nitya

151

Publications

4.9K

Citations

H-Index

Concepts

All Affiliations

University of California San Diego The University of Texas MD Anderson Cancer Center University of Utah Huntsman Cancer Institute Moffitt Cancer Center

About

Caitlin Costello is an author at University of California San Diego specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	1.6K
2	Health Sciences	7	7	1.2K
3	Cell Biology	2	2	72
4	Biochemistry	1	1	15
5	Blood Transplantation	1	1	10

Caitlin Costello

Publications

4.5K

Citations

H-Index

Page 1

	Year	Citations
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial Peter M. Voorhees, Jonathan L. Kaufman, Jacob P. Laubach, Blood	2020	653
Ipilimumab for Patients with Relapse after Allogeneic Transplantation Matthew S. Davids, Haesook T. Kim, Pavan Bachireddy, New England Journal of Medicine	2016	588
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline Joseph Mıkhael, Nofisat Ismaila, Matthew C. Cheung, Journal of Clinical Oncology	2019	319
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology Shaji Kumar, Natalie S. Callander, Melissa Alsina, Journal of the National Comprehensive Cancer Network Hematological MalignancyPlasma CellsBone Marrow FailureMedicineMalignant Blood Disorder	2017	277
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology Shaji Kumar, Natalie S. Callander, Kehinde Adekola, Journal of the National Comprehensive Cancer Network Hematological MalignancyBone Marrow FailureMedicineMalignant Blood DisorderHematology	2020	273
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018 Shaji Kumar, Natalie S. Callander, Melissa Alsina, Journal of the National Comprehensive Cancer Network Hematological MalignancyMedicineHematologyNccn Guidelines InsightsPathology	2018	203
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022 Natalie S. Callander, Muhamed Baljević, Kehinde Adekola, Journal of the National Comprehensive Cancer Network Hematological MalignancyNccn Guidelines® InsightsMedicineMalignant Blood DisorderMetronomic Therapy	2022	200
NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020 Shaji Kumar, Natalie S. Callander, Jens Hillengaß, Journal of the National Comprehensive Cancer Network Hematological MalignancyUrologyMedicineMalignant Blood DisorderHematology	2019	169
Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma Elisa Lazzari, Phoebe Mondala, Nathaniel P. Delos Santos, Nature Communications	2017	141
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial Peter M. Voorhees, Douglas W. Sborov, Jacob P. Laubach, The Lancet Haematology Transplantation-eligible PatientsHematological MalignancyTransplantationHealth SciencesImmunotherapy	2023	139

Page 1